Ceftolozane
The active component of a newer beta-lactam antibiotic designed with enhanced activity against Pseudomonas aeruginosa, typically used in combination with the beta-lactamase inhibitor tazobactam. It is indicated for complicated urinary tract and intra-abdominal infections as well as hospital-acquired pneumonia. It provides an important option for multidrug-resistant Pseudomonas infections.
Masse moléculaire
666,7000 g/mol
LogP
-3,20
TPSA
356,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …
Structure 2D
Cite this structure
Embed this structure
SMILES
Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1
InChI
InChI=1S/C23H30N12O8S2/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42)/b31-11-/t12-,18-/m1/s1
Molecular Formula
C23H30N12O8S2
HBD / HBA
7 / 16
Liaisons Rotatives
11
Atomes Lourds
45
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The active component of a newer beta-lactam antibiotic designed with enhanced activity against Pseudomonas aeruginosa, typically used in combination with the beta-lactamase inhibitor tazobactam. It is indicated for complicated urinary tract and intra-abdominal infections as well as hospital-acquired pneumonia. It provides an important option for multidrug-resistant Pseudomonas infections.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Yes, Ceftolozane is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103872. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 53234134. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftolozane"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftolozane/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftolozane/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftolozane/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftolozane"></drugfyi-drug>